On April 9, 2026, the Connecticut Senate voted 35 to 0 to expand the state's psychedelic therapy pilot program, extending eligibility to all adults 18 and older. The unanimous margin was not a fluke — it reflected years of legislative groundwork, a growing body of clinical evidence, and a bipartisan constituency that has come to see psychedelic-assisted therapy as a healthcare issue, not a culture war. Connecticut's vote is the most recent, and perhaps most striking, data point in a year that is beginning to look like a genuine inflection point for U.S. psychedelic policy.
To understand why 2026 is different, it helps to look at the full landscape of activity occurring in parallel: a landmark New Jersey law signed in January, a 67% increase in the DEA's psilocybin production quota, King County's enforcement deprioritization, expanding federal research infrastructure, and new academic data showing that psilocybin use is now mainstream-scale in America. These developments do not form a single coordinated movement. They are, however, moving in the same direction.
Connecticut: A Unanimous Signal
Connecticut's psilocybin pilot program predates the April 2026 vote; it was originally established to allow supervised therapeutic use for veterans and first responders with treatment-resistant conditions, anticipating eventual FDA approval of psilocybin as a prescription drug. The April 9 expansion broadens that access dramatically, removing the narrow eligibility criteria and opening the program to any adult 18 or older who meets clinical criteria for participation.
The 35-0 margin is notable for what it signals about the political durability of psychedelic policy. In other states, similar bills have passed along partisan lines or with modest margins. A unanimous vote in a state legislature — even a controlled pilot expansion, not full legalization — indicates that opposition to regulated therapeutic access has largely collapsed within that chamber. Legislators who might have faced blowback for a "yes" vote five years ago instead see political risk in opposing programs their constituents increasingly support.
New Jersey's Hospital-Based Model
Connecticut's vote follows New Jersey Governor Phil Murphy's signing of SB 2283 on January 20, 2026. The law allocates $6 million to establish a hospital-based psilocybin therapy pilot program — a structural choice with significant implications. By anchoring psilocybin services within existing hospital infrastructure rather than standalone therapy centers, New Jersey is betting that clinical legitimacy and patient safety are better served by embedding psychedelic care within conventional medicine.
The hospital-based framework also positions psilocybin within established insurance billing categories, potentially accelerating the path to insurance reimbursement — a key barrier that has limited access in Oregon's retail-model program, where out-of-pocket session costs can exceed $3,000. Whether New Jersey's model proves replicable will be closely watched by states that have moved more slowly on implementation.
The DEA Quota: A Bureaucratic Signal
Less visible than legislative action, but potentially more consequential for research velocity, was the Drug Enforcement Administration's decision to raise the legal psilocybin production quota from 30,000 grams to 50,000 grams — a 67% increase. DEA production quotas govern how much of a Schedule I substance can be manufactured legally in the United States in a given year. The quota constrains the supply available for clinical trials, pharmaceutical development, and federally sanctioned research.
A 67% increase does not necessarily translate into 67% more research immediately — licensed manufacturers must still apply for, and receive, DEA authorization to produce the additional quantity. But the quota increase signals that the agency anticipates sufficient legitimate demand to justify expanded production, and it removes a ceiling that had been limiting the growth of the clinical trial pipeline. Policy analysts tracking the DEA's posture note that such quota increases have historically preceded accelerated trial activity by 18 to 24 months.
King County: Enforcement Deprioritization as Policy
In March 2026, King County, Washington — which encompasses Seattle and is the most populous county in the Pacific Northwest — formally deprioritized enforcement of laws against personal psychedelic use across all substances, not just psilocybin. The resolution does not legalize possession; Washington state law still classifies psychedelics as controlled substances. What it does is direct county law enforcement to treat psychedelic possession as the lowest enforcement priority, effectively decoupling personal use from criminal consequence at the local level.
King County's move builds on a pattern established by Denver, Oakland, Santa Cruz, and other municipalities that have passed similar measures since 2019. Viewed in aggregate, these local deprioritization policies create a patchwork of de facto decriminalized zones that influence state-level conversations: legislators in states where multiple cities have deprioritized enforcement face different constituent dynamics than those in states where enforcement remains active.
The Usage Data: 11 Million Americans
The legislative and enforcement shifts are happening against a backdrop of dramatic growth in psilocybin use. Research from the University of Colorado Anschutz Medical Campus estimates that approximately 11 million American adults used psilocybin mushrooms in the past year — a figure that places psilocybin use at a population scale comparable to other mainstream behaviors. The CU Anschutz data is significant because it reframes the regulatory question: policymakers are no longer debating whether to permit a rare and exotic practice; they are contending with a behavior already widespread among their constituents, most of it occurring outside any supervised or therapeutic context.
The gap between the scale of actual use and the scale of regulated access is itself a policy argument. If 11 million Americans are using psilocybin annually — with no legal oversight, no trained guide, no clinical screening — a regulated access pathway arguably reduces rather than increases harm at the population level.
Federal Context: Research Infrastructure Expands
The state-level surge is occurring alongside cautious but real expansion of federal research infrastructure. The Oregon Health & Science University received the first National Institute on Drug Abuse (NIDA) grant specifically designed to study the outcomes of Oregon's legal psilocybin program — a $3.3 million award over five years that will fund rigorous real-world evaluation of the state's service center model. The OHSU grant, announced in February 2026, represents the first time federal research dollars have been explicitly directed at examining a state-legal psychedelic program.
ARPA-H, the federal Advanced Research Projects Agency for Health, has committed $100 million to behavioral health research, a category that psychedelic therapy advocates are actively working to ensure includes psilocybin-assisted psychotherapy trials. The VA's ongoing psychedelic research program, the expressed interest of multiple senior officials in accelerating psychedelic research timelines, and the bipartisan veteran-welfare framing that has defined much of the federal conversation all suggest that federal posture is shifting — if slowly and with significant institutional resistance — from scheduling enforcement toward research facilitation.
What Changes, and What Doesn't
It is important to be precise about what this legislative surge does and does not mean. Connecticut's expansion and New Jersey's law both operate under a pilot framework: they permit supervised therapeutic access, not personal use or retail sale. Psilocybin remains a Schedule I controlled substance under federal law, and no state-level action changes that federal classification. Individuals who use psilocybin outside of a licensed therapeutic setting — the 11 million Americans represented in the CU Anschutz data — remain technically subject to federal prosecution, regardless of state or local policy.
What is changing is the institutional environment in which federal reclassification decisions will eventually be made. When 35 Connecticut senators vote unanimously to expand therapeutic access, when New Jersey funds a hospital program, when King County deprioritizes enforcement, and when NIDA funds research into Oregon's legal program, the accumulated institutional weight of these decisions shifts the context for FDA review and DEA scheduling reconsideration. Policy rarely moves in a straight line, but the trajectory through the first quarter of 2026 is unmistakably toward expansion.